[go: up one dir, main page]

CL2016000400A1 - Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica. - Google Patents

Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica.

Info

Publication number
CL2016000400A1
CL2016000400A1 CL2016000400A CL2016000400A CL2016000400A1 CL 2016000400 A1 CL2016000400 A1 CL 2016000400A1 CL 2016000400 A CL2016000400 A CL 2016000400A CL 2016000400 A CL2016000400 A CL 2016000400A CL 2016000400 A1 CL2016000400 A1 CL 2016000400A1
Authority
CL
Chile
Prior art keywords
acute
diaminopyridine
modulators
receptor
sub
Prior art date
Application number
CL2016000400A
Other languages
English (en)
Inventor
Anthony P Ford
Bruce G Mccarthy
Original Assignee
Afferent Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52480919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000400(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Afferent Pharmaceuticals Inc filed Critical Afferent Pharmaceuticals Inc
Publication of CL2016000400A1 publication Critical patent/CL2016000400A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

METODOS PARA TRATAR TOS CRONICA O PARA TRATAR TOS AGUDA, SUBAGUDA O CRONICA, SUBYACENTE A LA HIPERSENSIBILIDAD NEURONAL, QUE COMPRENDE ADMINISTRAR UN COMPUESTO DERIVADO DE DIAMINOPIRIDINA O SUS SALES; Y EL USO DE DICHOS COMPUESTOS DERIVADOS DE DIAMINOPIRIDINA O SUS SALES.
CL2016000400A 2013-08-23 2016-02-22 Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica. CL2016000400A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361869174P 2013-08-23 2013-08-23

Publications (1)

Publication Number Publication Date
CL2016000400A1 true CL2016000400A1 (es) 2017-01-20

Family

ID=52480919

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2016000400A CL2016000400A1 (es) 2013-08-23 2016-02-22 Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica.
CL2018002138A CL2018002138A1 (es) 2013-08-23 2018-08-08 Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, subaguda o crónica.(divisional solicitud 201600400)
CL2018002137A CL2018002137A1 (es) 2013-08-23 2018-08-08 Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, subaguda o crónica.(divisional solicitud 201600400)

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2018002138A CL2018002138A1 (es) 2013-08-23 2018-08-08 Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, subaguda o crónica.(divisional solicitud 201600400)
CL2018002137A CL2018002137A1 (es) 2013-08-23 2018-08-08 Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, subaguda o crónica.(divisional solicitud 201600400)

Country Status (20)

Country Link
US (3) US9284279B2 (es)
EP (2) EP3865134A1 (es)
JP (3) JP6546592B2 (es)
KR (1) KR102196885B1 (es)
CN (1) CN105682659B (es)
AU (1) AU2014308606B2 (es)
CA (1) CA2921395C (es)
CL (3) CL2016000400A1 (es)
CR (1) CR20160093A (es)
IL (1) IL244131B (es)
MX (1) MX367657B (es)
MY (1) MY195728A (es)
NI (1) NI201600029A (es)
NZ (1) NZ716977A (es)
PE (1) PE20160431A1 (es)
PH (1) PH12016500357A1 (es)
RU (1) RU2650118C2 (es)
SG (1) SG11201601145RA (es)
UA (1) UA118851C2 (es)
WO (1) WO2015027212A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102196885B1 (ko) 2013-08-23 2020-12-30 애퍼런트 파마슈티컬스 인크. 급성, 아급성 또는 만성 기침의 치료를 위한 디아미노피리미딘 p2x3 및 p2x2/3 수용체 조절제
PL3104853T3 (pl) 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
CA2938996A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Methods for the treatment of lung diseases with mast cell stabilizers
WO2017011729A1 (en) 2015-07-16 2017-01-19 Patara Pharma, LLC Combination therapies for the treatment of lung diseases
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US11260056B2 (en) * 2015-09-29 2022-03-01 Afferent Pharmaceuticals, Inc. Diaminopyrimidine P2X3 and P2X2/3 receptor modulators for use in the treatment of cough
US9907795B2 (en) * 2016-01-08 2018-03-06 Nerre Therapeutics Limited Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
CA3018180C (en) 2016-03-25 2024-02-20 Ronald Charles Hawley Pyrimidines and variants thereof, and uses therefor
AU2017321495A1 (en) 2016-08-31 2019-03-21 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
WO2018111738A1 (en) * 2016-12-15 2018-06-21 Afferent Pharmaceuticals, Inc. Substituted pyrazole-pyrimidines, variants thereof, and uses therefore
MX381790B (es) * 2016-12-20 2025-03-13 Afferent Pharmaceuticals Inc Sales cristalinas y polimorfos de un antagonista de p2x3.
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
CN108904507A (zh) * 2018-02-11 2018-11-30 赖英杰 P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用
CN112004551A (zh) 2018-03-15 2020-11-27 丹米尔治疗有限责任公司 3”,5”-二烷氧基苯甲酰基-3’-氨基-3’-脱氧腺苷-5’-三磷酸及其药物用途
US11584724B2 (en) 2018-04-23 2023-02-21 Merck Sharp & Dohme Llc Process for synthesis of a phenoxy diaminopyrimidine compound
BR112020022340A2 (pt) 2018-05-15 2021-02-02 Bayer Aktiengesellschaft benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas
JP2021523919A (ja) 2018-05-15 2021-09-09 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 神経線維感作に関連する疾患を治療するための１，３−チアゾール−２−イル置換ベンズアミド
IL318587A (en) * 2018-07-23 2025-03-01 Trevi Therapeutics Inc Treatment of chronic cough, shortness of breath and wheezing
EP3862000B1 (en) * 2018-10-05 2023-10-18 Shionogi & Co., Ltd Medicine for treating chronic cough
CN113727716A (zh) 2019-02-25 2021-11-30 贝卢斯医疗咳嗽病公司 采用p2x3调节剂的治疗
WO2020221276A1 (zh) * 2019-04-30 2020-11-05 北京泰德制药股份有限公司 二氨基嘧啶类化合物的盐、其固体形式及其制备方法和用途
CN114007619B (zh) * 2019-04-30 2024-08-06 北京泰德制药股份有限公司 二氨基嘧啶类化合物治疗咳嗽的方法
BR112022004398A2 (pt) 2019-09-19 2022-05-31 Shionogi & Co Cristal de derivado de 1,3,5-triazina ou solvato do mesmo e método para produção do mesmo
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine
CN111635368B (zh) * 2020-06-12 2021-06-29 东莞市东阳光仿制药研发有限公司 一种胺化合物的制备方法
CN120019423A (zh) 2022-10-12 2025-05-16 软银集团股份有限公司 信息处理系统、信息处理装置、控制装置及程序

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20120901T1 (hr) 2004-03-05 2012-12-31 F. Hoffmann - La Roche Ag Diaminopirimidini kao p2x3 i p2x2/3
AU2005266887B2 (en) 2004-07-22 2011-08-18 Duska Scientific Co. Method of diagnosing, monitoring and treating pulmonary diseases
WO2007025901A1 (en) 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
PL1924264T3 (pl) 2005-09-01 2014-03-31 Hoffmann La Roche Diaminopirymidyny jako modulatory P2X<sub>3</sub> I P2X<sub>2/3</sub>
CA2619919C (en) * 2005-09-01 2014-04-01 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
ATE529413T1 (de) 2005-09-01 2011-11-15 Hoffmann La Roche Verfahren zur synthese von aryloxydiaminopyrimidinen
MX2009003257A (es) 2006-10-04 2009-04-07 Hoffmann La Roche Procedimiento para la sintesis de derivados de fenoxi diaminopirimidina.
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
US9550763B2 (en) * 2012-02-09 2017-01-24 Shionogi & Co., Ltd. Heterocyclic ring and carbocyclic derivative
KR102196885B1 (ko) * 2013-08-23 2020-12-30 애퍼런트 파마슈티컬스 인크. 급성, 아급성 또는 만성 기침의 치료를 위한 디아미노피리미딘 p2x3 및 p2x2/3 수용체 조절제
US9133647B2 (en) * 2013-10-11 2015-09-15 Nexkey, Inc. NFC or BLE based contactless lock with charge monitoring of its energy storage

Also Published As

Publication number Publication date
JP7423725B2 (ja) 2024-01-29
AU2014308606A1 (en) 2016-03-10
IL244131A0 (en) 2016-04-21
CA2921395A1 (en) 2015-02-26
US20160263112A1 (en) 2016-09-15
CR20160093A (es) 2016-08-26
CN105682659A (zh) 2016-06-15
CN105682659B (zh) 2019-12-10
US9724346B2 (en) 2017-08-08
CL2018002138A1 (es) 2018-10-05
PE20160431A1 (es) 2016-06-02
CA2921395C (en) 2022-04-26
US10206922B2 (en) 2019-02-19
WO2015027212A1 (en) 2015-02-26
KR20160052581A (ko) 2016-05-12
US20150057299A1 (en) 2015-02-26
PH12016500357A1 (en) 2016-05-16
NZ716977A (en) 2017-09-29
EP3035932A1 (en) 2016-06-29
JP7210348B2 (ja) 2023-01-23
JP2019112459A (ja) 2019-07-11
EP3035932A4 (en) 2017-01-04
UA118851C2 (uk) 2019-03-25
CL2018002137A1 (es) 2018-10-05
AU2014308606B2 (en) 2017-08-03
HK1222126A1 (zh) 2017-06-23
EP3865134A1 (en) 2021-08-18
RU2016105581A (ru) 2017-09-28
IL244131B (en) 2019-06-30
JP2016528301A (ja) 2016-09-15
US20170326142A1 (en) 2017-11-16
MX2016002289A (es) 2016-09-06
KR102196885B1 (ko) 2020-12-30
US9284279B2 (en) 2016-03-15
MY195728A (en) 2023-02-07
RU2650118C2 (ru) 2018-04-09
SG11201601145RA (en) 2016-03-30
JP2023002662A (ja) 2023-01-10
MX367657B (es) 2019-08-30
NI201600029A (es) 2017-09-22
JP6546592B2 (ja) 2019-07-17

Similar Documents

Publication Publication Date Title
CL2016000400A1 (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica.
MX2022014331A (es) Metodos y composiciones para el tratamiento de trastornos epilepticos.
CL2018001181A1 (es) Inhibidores de ret
UY37036A (es) Compuestos inhibidores de la quinasa de unión a tank
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
MX2017005457A (es) Metodos y compuestos agonistas de gip.
CL2015002855A1 (es) Derivados de oxopiridina sustituida.
CL2016002169A1 (es) Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados.
MX390517B (es) Uso de moduladores del receptor de glucocorticoides para potenciar inhibidores de puntos de regulacion.
MX2017003359A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX2021011939A (es) Compuestos neuroactivos y metodos de uso de los mismos.
MX2017001553A (es) Derivados de heterociclico opcionalmente condensados de pirimidina utiles para el tratamiento de enfermedades inflamatorias, metabolicas oncologicas y autoinmunitarias.
EA201891626A1 (ru) Ингибиторы тирозинкиназы брутона
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
MX390084B (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CR20160047A (es) Inhibidores de rorc2 y sus métodos de uso
BR112017011168A2 (pt) medicamentos para retardar a doença de parkinson
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
CL2016001098A1 (es) Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.